| etoposide oral / Generic mfg. |
ChiCTR2100053926: Oral etoposide combined with realgar natural indigo tablets and all-trans retinoic acid in the treatment of high-risk acute promyelocytic leukemia |
|
|
| Recruiting | 4 | 26 | | Oral etoposide combined with realgar natural indigo tablets and all-trans retinoic acid | Peking University People's Hospital; Peking University People's Hospital, Research and development fund of Peking University People's Hospital (Scientific Research) | high-risk acute promyelocytic leukemia | | | | |
JCOG0907, jRCTs031180243: A Non-Randomized Validation Trial of a Therapy Incorporating Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Adult T-Cell Leukemia and Lymphoma |
|
|
| Completed | 3 | 110 | Japan | carboplatin - Generic mfg., cytarabine - Generic mfg., methotrexate - Generic mfg., prednisolone - Generic mfg., vincristine - Generic mfg., cyclophosphamide - Generic mfg., doxorubicin hydrochloride - Generic mfg., Cymerin (ranimustine) - Mitsubishi Tanabe, vindesine - Generic mfg., etoposide oral - Generic mfg., busulfan - Generic mfg., cyclosporine - Generic mfg., tacrolimus oral - Generic mfg., fludarabine oral - Generic mfg., prednisolone - Generic mfg., Lioplim (filgrastim) - Abbott, Neu-up (nartograstim) - Yakult Honsha, Granocyte (lenograstim) - Roche, Poteligeo (mogamulizumab-kpkc) - Kyowa Kirin | Saitama Medical University International Medical Center | Adult T-cell leukemia-lymphoma | | | | |
| Recruiting | 3 | 330 | Japan | carboplatin - Generic mfg., etoposide oral - Generic mfg., cisplatin - Generic mfg., Tecentriq (atezolizumab) - Roche, Imfinzi (durvalumab) - AstraZeneca | Dokkyo Medical University Hospital, National Cancer Center Japan | Extensive stage small cell lung cancer | | | | |
| Completed | 3 | 258 | | oral etoposide maintenance ;observation | West China Hospital; Level of the institution：, None | small cell lung cancer | | | | |
NCT01595048 / 2010-019224-31: Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia |
|
|
| Active, not recruiting | 2/3 | 640 | US, Canada, RoW | Rituximab, MOAB IDEC-C2B8, Prednisone, Etoposide, Lastet, Doxorubicin Hydrochloride, Cytarabine, CHX-3311, U-19920, Vincristine Sulfate, Kyocristine, Oncovin, VCR, Vincasar, Cyclophosphamide, Methotrexate, Methylprednisolone, MePRDL, Leucovorin Calcium, CF, Therapeutic Hydrocortisone, Aeroseb-HC, Cetacort, HC, Laboratory Biomarker Analysis | Children's Oncology Group, National Cancer Institute (NCI) | Childhood B Acute Lymphoblastic Leukemia, Childhood Burkitt Leukemia, Childhood Diffuse Large Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Stage III Childhood Large Cell Lymphoma, Stage IV Childhood Large Cell Lymphoma | 12/20 | 12/20 | | |
NCT01064466: Pharmacogenomics IND EXEMPT SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms |
|
|
| Active, not recruiting | 2/3 | 600 | US | ETOPOSIDE - Usual, Etoposide Injection Chemotherapy, ETOPOSIDE - Study, Etoposide Capsule Chemotherapy | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, UnitedHealthcare | Small Cell Lung Cancer | 11/24 | 12/24 | | |
ChiCTR-TNC-09000357: Maintenance treatment with orally etoposide for extensive stage small cell lung cancer: a phase II study |
|
|
| Completed | 2 | 30 | | EP regimen: Etoposide 100mg/m2, day 1-4 + Cisplatin 80mg/m2, day1 or divided to 3 days, repeated every 21 days for 4 cycles. Maintenance therapy: Orally Etoposide 50mg/m2, day1-14, repeated every 21 days till tumor progression is detected. | West China hospital, Sichuan University; Level of the institution：, self-funded | Small cell lung cancer (Extensive stage) | | | | |
ChiCTR-IIR-17012870: A prospective and multicenter study of apatinib mesylate combine with etoposide orally to treat platinum-resistant relapse ovarian cancer |
|
|
| Not yet recruiting | 2 | 60 | | Apatinib Mesylate Tablets: 500mg, PO.QD, continuous administration; Etoposide Capsules 100mg, PO.Qd, D1-D10, Q3W. The tolerance of Apatinib Mesylate Tablets is evaluated at 14th day after administration, subjects with well tolerance will increase the dose to 750mg, qd. Untill the disease progress. ;Etoposide Capsules 100mg, PO.Qd, D1-D10, Q3W. Untill the disease progress. | GuangXi Medical University Affiliated Tumor Hospital; GuangXi Medical University Affiliated Tumor Hospital, Self-financing | ovarian cancer | | | | |
ChiCTR1800019970: Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, Controlled, prospective study |
|
|
| Not yet recruiting | 2 | 78 | | Apatinib combined with oral etoposide ;oral etoposide | Affiliated Cancer Hospital of Harbin Medical University; Affiliated Cancer Hospital of Harbin Medical University, By oneself | platinum-resistant or platinum-refractory ovarian cancer | | | | |
ChiCTR1800018497: Apatinib combined with oral etoposide in patients as second- or later-line with triple negativebreast cancer: a phase II, single-arm, prospective study |
|
|
| Recruiting | 2 | 40 | | Apatinib combined with oral etoposide | Affiliated Cancer Hospital of Harbin Medical University; Affiliated Cancer Hospital of Harbin Medical University, By oneself | Triple negativebreast cancer | | | | |
ChiCTR-IIR-16008431: A randomized control study of maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus cisplatin in extensive small-cell lung cancer |
|
|
| Not yet recruiting | 2 | 100 | | maintenance with oral etoposide ;no | Zhejiang Cancer Hospital; Zhejiang Cancer Hospital, researcher | lung cancer | | | | |
NCT04217798: Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer |
|
|
| Recruiting | 2 | 36 | RoW | Niraparib, oral etoposide | Peking Union Medical College Hospital, Zai Lab (Shanghai) Co., Ltd. | Ovarian Cancer | 03/22 | 06/22 | | |
NCT04452370: Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer |
|
|
| Recruiting | 2 | 100 | RoW | oral etoposide + anlotinib, there is no other intervention name | Chinese Academy of Medical Sciences | Triple Negative Breast Cancer | 07/22 | 07/23 | | |
| Completed | 2 | 18 | Europe | metronomic therapy, Dociton, Celebrex, Endoxan, Lastet, Vinblastinsulfat Teva | University of Cologne | Recurrent Neuroblastoma | 06/23 | 06/23 | | |
NCT05685550: Safety and Efficacy of Oral Etoposide Combined With Antirotinib and Envollizumab in Elderly Patients With Lung Cancer |
|
|
| Not yet recruiting | 2 | 30 | NA | Toposide capsules combined with anrotinib and Emvolizumab group, Combined treatment group | Tianjin Medical University Cancer Institute and Hospital | Progression Free Survival(PFS) | 12/23 | 05/24 | | |
NCT06463171: Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer |
|
|
| Not yet recruiting | 2 | 60 | RoW | Almonertinib, Lastet | Shanghai Pulmonary Hospital, Shanghai, China, Shanghai Zhongshan Hospital, The First Affiliated Hospital of Xiamen University | Lung Cancer Non-small Cell Stage IV | 06/26 | 06/26 | | |
NCT06436144: Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC |
|
|
| Not yet recruiting | 2 | 93 | NA | Osimertinib, Etoposide Soft Capsules | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Non Small Cell Lung Cancer, EGFR Gene Mutation, Non Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV | 06/29 | 12/29 | | |
NCT04501718: Apatinib Combined With Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children |
|
|
| Recruiting | 2 | 44 | RoW | Apatinib Combined With Temozolomide and Etoposide Capsules | Beijing Sanbo Brain Hospital | Recurrent Medulloblastoma | 08/24 | 08/24 | | |
NCT04804007: Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT |
|
|
| Recruiting | 2 | 64 | US | Etoposide | Nabil Adra | Germ Cell Tumor, Non-seminomatous Germ Cell Tumor, Ovarian Germ Cell Tumor | 12/27 | 12/28 | | |
ChiCTR2400083981: Phase II Clinical Study of Almonertinib in Combination with LASTET in the First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer with EGFR Mutations |
|
|
| Not yet recruiting | 2 | 60 | | Almonertinib in Combination with LASTET | shanghai pulmonary hospital; shanghai pulmonary hospital, Shanghai Pulmonary Hospital | Non-Small Cell Lung Cancer | | | | |
TUC-TOC, NCT05955170: Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer |
|
|
| Recruiting | 2 | 66 | Europe | Tucatinib in Combination of Oral VP16 and trastuzumab | Institut Curie, Seagen Inc. | HER2-positive Breast Cancer | 12/26 | 12/27 | | |
MEPENDAX, NCT06485908: Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma |
|
|
| Not yet recruiting | 1/2 | 40 | NA | administration of axitinib in combination with etoposide | Assistance Publique Hopitaux De Marseille | Medulloblastoma, Ependymoma | 04/26 | 01/30 | | |
NCT02342782: Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma |
|
|
| Active, not recruiting | 1 | 20 | US | Yttrium Y 90 Basiliximab, 90Y Basiliximab, Carmustine, FDA 0345, BCNU, BiCNU, Etoposide, Lastet, VP-16, Cytarabine, CHX-3311, U-19920, Ara-C, Cytosar, Melphalan, Alkeran, L-PAM, Autologous Hematopoietic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Laboratory Biomarker Analysis, Pharmacological Study, pharmacological studies | City of Hope Medical Center, National Cancer Institute (NCI) | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma | 09/20 | 12/24 | | |
NCT02337985: Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma |
|
|
| Active, not recruiting | 1 | 10 | US | Prednisone, Rituximab, MOAB IDEC-C2B8, Etoposide, Lastet, VP 16, Doxorubicin Hydrochloride, Adriamycin, Vincristine Sulfate, Kyocristine, Oncovin, VCR, Vincasar, Cyclophosphamide, Filgrastim, G-CSF, Nivestim, r-metHuG-CSF, Neupogen, Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells, lentivirus-transduced hematopoietic progenitor cells | City of Hope Medical Center, National Cancer Institute (NCI) | AIDS-Related Burkitt Lymphoma, AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma, HIV Infection, AIDS Related Non-Hodgkin Lymphoma | 12/24 | 12/24 | | |
| Active, not recruiting | 1 | 10 | US | Etoposide; Oral, 50 Mg, Etoposide phosphate, Focused ultrasound with neuro-navigator-controlled sonication | Cheng-Chia (Fred) Wu, Focused Ultrasound Foundation | Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant | 01/25 | 01/27 | | |
| Not yet recruiting | N/A | 96 | | Etoposide tablets; Tongbi San+Etoposide tablets | Nanyang second general hospital; Nanyang second general hospital, Hospital level project of Nanyang Second People's Hospital | Acute gouty arthritis | | | | |